Fulgent to Announce Third Quarter 2024 Financial Results on Friday, November 8, 2024
Fulgent Genetics (NASDAQ: FLGT) has announced it will release its third quarter 2024 financial results before the market opens on Friday, November 8, 2024. The company, which operates a laboratory services business and a therapeutic development business, will host a conference call for investors at 8:30 AM ET (5:30 AM PT) on the same day.
Management will discuss the results and answer questions during the call. Investors can access the live audio webcast through the Investor Relations section of Fulgent's website at http://ir.fulgentgenetics.com. An audio replay will also be available at the same location following the call.
Fulgent Genetics (NASDAQ: FLGT) ha annunciato che rilascerà i suoi risultati finanziari del terzo trimestre 2024 prima dell'apertura del mercato venerdì 8 novembre 2024. L'azienda, che gestisce un'attività di servizi di laboratorio e un'attività di sviluppo terapeutico, terrà una conferenza telefonica per gli investitori alle 8:30 AM ET (5:30 AM PT) dello stesso giorno.
La direzione discuterà dei risultati e risponderà alle domande durante la chiamata. Gli investitori possono accedere alla diretta audio tramite la sezione Relazioni con gli Investitori del sito web di Fulgent all'indirizzo http://ir.fulgentgenetics.com. Una registrazione audio sarà disponibile anche nello stesso luogo subito dopo la chiamata.
Fulgent Genetics (NASDAQ: FLGT) ha anunciado que publicará sus resultados financieros del tercer trimestre de 2024 antes de la apertura del mercado el viernes 8 de noviembre de 2024. La compañía, que opera un negocio de servicios de laboratorio y un negocio de desarrollo terapéutico, llevará a cabo una llamada de conferencia para inversores a las 8:30 AM ET (5:30 AM PT) el mismo día.
La dirección discutirá los resultados y responderá preguntas durante la llamada. Los inversores pueden acceder a la transmisión de audio en vivo a través de la sección de Relaciones con Inversores del sitio web de Fulgent en http://ir.fulgentgenetics.com. Una grabación de audio también estará disponible en el mismo lugar después de la llamada.
풀젠트 유전자 (NASDAQ: FLGT)는 2024년 3분기 재무 결과를 2024년 11월 8일 금요일 시장 개장 전에 발표할 것이라고 발표했습니다. 실험실 서비스 및 치료 개발 비즈니스를 운영하는 이 회사는 같은 날 오전 8시 30분 ET (오전 5시 30분 PT)에 투자자를 위한 컨퍼런스 콜을 개최할 예정입니다.
경영진은 결과를 논의하고 호출 중에 질문에 답할 것입니다. 투자자는 Fulgent 웹사이트의 투자자 관계 섹션을 통해 실시간 오디오 웹캐스트에 접속할 수 있습니다: http://ir.fulgentgenetics.com. 통화 후 동일한 위치에서 오디오 재생도 제공됩니다.
Fulgent Genetics (NASDAQ: FLGT) a annoncé qu'elle publiera ses résultats financiers pour le troisième trimestre 2024 avant l'ouverture des marchés le vendredi 8 novembre 2024. La société, qui opère dans les services de laboratoire et le développement thérapeutique, animera une conférence téléphonique pour les investisseurs à 8h30 ET (5h30 PT) le même jour.
La direction discutera des résultats et répondra aux questions durant l'appel. Les investisseurs peuvent accéder à la webconférence audio en direct via la section Relations avec les Investisseurs du site web de Fulgent à l'adresse http://ir.fulgentgenetics.com. Un enregistrement audio sera également disponible au même endroit après l'appel.
Fulgent Genetics (NASDAQ: FLGT) hat bekannt gegeben, dass es seine Finanzergebnisse für das dritte Quartal 2024 vor der Markteröffnung am Freitag, den 8. November 2024, veröffentlichen wird. Das Unternehmen, das sowohl im Bereich Laborservices als auch in der therapeutischen Entwicklung tätig ist, wird am selben Tag um 8:30 Uhr ET (5:30 Uhr PT) eine Telefonkonferenz für Investoren abhalten.
Die Geschäftsführung wird die Ergebnisse besprechen und während des Anrufs Fragen beantworten. Investoren können auf die Live-Audioübertragung über den Bereich Investor Relations der Website von Fulgent unter http://ir.fulgentgenetics.com zugreifen. Eine Audio-Wiedergabe wird auch an derselben Stelle nach dem Anruf verfügbar sein.
- None.
- None.
The call may be accessed through a live audio webcast on the Investor Relations section of the Company’s website, http://ir.fulgentgenetics.com. An audio replay will be available at the same location.
About Fulgent
Fulgent is a technology-based company with a well-established laboratory services business and a therapeutic development business. Fulgent’s laboratory services business, which was formerly referred to as the clinical diagnostic business, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Fulgent’s therapeutic development business is focused on developing drug candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The Company aims to transform from a genomic diagnostic business into a fully integrated precision medicine company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241017119356/en/
Investor Relations Contact:
The Blueshirt Group
Melanie Solomon, melanie@blueshirtgroup.com
Source: Fulgent Genetics, Inc.
FAQ
When will Fulgent Genetics (FLGT) release its Q3 2024 financial results?
What time is Fulgent Genetics' (FLGT) Q3 2024 earnings call scheduled for?
How can investors access Fulgent Genetics' (FLGT) Q3 2024 earnings call?
Will there be a replay available for Fulgent Genetics' (FLGT) Q3 2024 earnings call?
